Beer TM - Search Results

1

Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer.

Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Schnadig ID, et al. Among authors: beer tm. Cancer. 2008 Oct 15;113(8):2205-14. doi: 10.1002/cncr.23856. Cancer. 2008. PMID: 18780322 Free PMC article.

2

A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation.

Beer TM, Munar M, Henner WD. Beer TM, et al. Cancer. 2001 Jun 15;91(12):2431-9. Cancer. 2001. PMID: 11413535 Clinical Trial.

3

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.

Beer TM, Lemmon D, Lowe BA, Henner WD. Beer TM, et al. Cancer. 2003 Mar 1;97(5):1217-24. doi: 10.1002/cncr.11179. Cancer. 2003. PMID: 12599228 Free article.

4

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.

Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Garzotto M, et al. Among authors: beer tm. Cancer. 2003 Oct 1;98(7):1417-22. doi: 10.1002/cncr.11668. Cancer. 2003. PMID: 14508828 Free article.

5

Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.

Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Beer TM, et al. Cancer. 2004 Feb 15;100(4):758-63. doi: 10.1002/cncr.20024. Cancer. 2004. PMID: 14770432 Free article. Clinical Trial.

6

Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.

el-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, Beer TM. el-Geneidy M, et al. Among authors: beer tm. BJU Int. 2004 Mar;93(4):510-5. doi: 10.1111/j.1464-410x.2003.04669.x. BJU Int. 2004. PMID: 15008720

7

Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.

Beer TM, Berry W, Wersinger EM, Bland LB. Beer TM, et al. Clin Prostate Cancer. 2003 Dec;2(3):167-72. doi: 10.3816/cgc.2003.n.025. Clin Prostate Cancer. 2003. PMID: 15040860 Clinical Trial.

8

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. Fromme EK, et al. Among authors: beer tm. J Clin Oncol. 2004 Sep 1;22(17):3485-90. doi: 10.1200/JCO.2004.03.025. J Clin Oncol. 2004. PMID: 15337796

9

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Beer TM, et al. Br J Cancer. 2004 Oct 18;91(8):1425-7. doi: 10.1038/sj.bjc.6602198. Br J Cancer. 2004. PMID: 15467765 Free PMC article.

10

Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen.

Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, Garzotto M. Panagiotou I, et al. Among authors: beer tm. Oncology. 2004;67(3-4):194-202. doi: 10.1159/000081317. Oncology. 2004. PMID: 15557778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters